Published in final edited form as:

Science. 2002 March 22; 295(5563): 2255–2258. doi:10.1126/science.1068819.

Adaptive Immune Response of V γ 2V δ 2⁺ T Cells During Mycobacterial Infections

Yun Shen^{1,2}, Dejiang Zhou^{1,2}, Liyou Qiu^{1,2}, Xiaomin Lai^{1,2}, Meredith Simon³, Ling Shen², Zhongchen Kou^{1,2}, Qifan Wang^{1,2}, Liming Jiang^{1,2}, Jim Estep⁴, Robert Hunt⁴, Michelle Clagett⁴, Prabhat K. Sehgal³, Yunyaun Li^{1,2}, Xuejun Zeng^{1,2}, Craig T. Morita⁵, Michael B. Brenner⁶, Norman L. Letvin², and Zheng W. Chen^{1,2,*}

¹ Tuberculosis Research Unit, Harvard Medical School, Boston, MA 02115, USA

² Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA

³ New England Regional Primate Research Center, Southboro, MA 01772, USA

⁴ Battelle Medical Research and Evaluation Facility, Battelle Memorial Institute, Columbus, Ohio 43201, USA

⁵ Division of Rheumatology, Department of Internal Medicine, and the Interdisciplinary Group on Immunology, University of Iowa, Iowa City, IA 52242, USA

⁶ Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA

Abstract

To examine the role of T cell receptor (TCR) in $\gamma\delta$ T cells in adaptive immunity, a macaque model was used to follow V γ 2V δ 2⁺ T cell responses to mycobacterial infections. These phosphoantigen-specific $\gamma\delta$ T cells displayed major expansion during *Mycobacterium bovis* Bacille Calmette-Guérin (BCG) infection and a clear memory-type response after BCG reinfection. Primary and recall expansions of V γ 2V δ 2⁺ T cells were also seen during *Mycobacterium tuberculosis* infection of naïve and BCG-vaccinated macaques, respectively. This capacity to rapidly expand coincided with a clearance of BCG bacteremia and immunity to fatal tuberculosis in BCG-vaccinated macaques. Thus, V γ 2V δ 2⁺ T cells may contribute to adaptive immunity to mycobacterial infections.

The majority of circulating $\gamma\delta$ T cells in humans express a TCR heterodimer comprised of V γ 2 and V δ 2 segments. Recent in vitro studies have demonstrated that human V γ 2V δ 2⁺ T cells recognize small organic phosphate antigens (1–6) from microbes and other nonpeptide molecules such as alkylamines and aminobisphosphonates (7,8). The recognition of these nonpeptide antigens by V γ 2V δ 2⁺ T cells does not require antigen processing or presentation by major histocompatibility complex (MHC) or CD1 molecules (9). *Mycobacterium tuberculosis*-induced tuberculosis remains a leading cause of morbidity and mortality among infectious diseases. Immune correlates of protection against tuberculosis remain poorly characterized in humans. Detailed analyses of V γ 2V δ 2⁺ T cell responses and their potential role in microbial infections have not been well documented in humans [see review, (10)], despite compelling evidence that murine $\gamma\delta$ T cells provide protection against a range of infections (11–16). The capability of V γ 2V δ 2⁺ T cells to mount a memory response after microbial reinfection or reactivation has not been demonstrated. Relevant studies in mice cannot be performed because murine $\gamma\delta$ T cells do not express the homolog of the V γ 2V δ 2⁺

*To whom correspondence should be addressed. zchen@caregroup.harvard.edu.

TCR, and there is no functional equivalent for these cells, so far, identified in mice. We reasoned that nonhuman primates could provide a good model in which to determine the nature of the immune responses of $V\gamma 2V\delta 2^+$ T cells in a mycobacterial infection.

To examine a primary $\gamma\delta$ T cell response during mycobacterial infection, macaques were inoculated with BCG (17) and assessed for changes in their $\gamma\delta$ T cell repertoire (18). Striking expansions of circulating $V\gamma 2V\delta 2^+$ T cells were detected in the blood of these monkeys after BCG inoculation, whereas there was no apparent increase in other circulating $V\gamma^+$ or $V\delta^+$ T cells (Fig. 1A). The percent of peripheral blood $CD3^+$ T cells that were $V\gamma 2V\delta 2^+$ and the absolute number of circulating $V\gamma 2V\delta 2^+$ T cells increased by up to 25-fold and as much as a 200-fold, respectively (Fig. 1A). The expansion of $V\gamma 2V\delta 2^+$ T cells was most evident 3 to 5 weeks after BCG inoculation (Fig. 1A). The expansion of circulating $V\gamma 2V\delta 2^+$ T cells in the infected macaques indicated the development of primary response of these cells during a mycobacterial infection.

$V\gamma 2V\delta 2^+$ T cells compose the majority of the human $\gamma\delta$ T cell population in the circulation. We next examined whether macaque $V\gamma 2V\delta 2^+$ T cells in tissue compartments had expanded during a BCG infection. An increase in pulmonary $V\gamma 2V\delta 2^+$ T cells was evident after intravenous BCG inoculation (Fig. 1B). Expansion of the $V\gamma 2V\delta 2$ T cell subpopulation was also apparent within intestinal mucosae (Fig. 1B). Despite this expansion in blood and tissue sites, only a subtle expansion of $V\gamma 2V\delta 2^+$ T cells was observed in organized lymph nodes of the same monkeys. These findings suggest that the $V\gamma 2V\delta 2^+$ T cells in mucosal but not peripheral lymph node tissues could expand in response to a mycobacterial infection. The expansion of $V\gamma 2V\delta 2^+$ T cells in these mucosal areas may result from their local proliferation in response to the BCG infection. In addition, $V\gamma 2V\delta 2^+$ T cells may also accumulate in these tissue sites through the recruitment from the circulating pool of $\gamma\delta$ T cells.

The hallmarks of memory T cell responses include their antigen-specific persistence after the initial infection and the rapid and prolonged recall responses upon reinfection. To determine whether $V\gamma 2V\delta 2^+$ T cell responses possessed the capacity for immunological memory, macaques that had previously been infected with BCG were inoculated again with BCG and were assessed for memory $V\gamma 2V\delta 2^+$ T cell responses. As early as 4 to 6 days after the second BCG inoculation, a marked expansion of $V\gamma 2V\delta 2^+$ T cells was apparent in the blood of the monkeys (Fig. 2). The $V\gamma 2V\delta 2^+$ T cell expansions during the BCG reinfection were 2 to 9 times as large as those seen during primary infection (Fig. 2). The expansion of these cells persisted for as long as 7 months after the second BCG inoculation (Fig. 2). Analyses of TCR sequences revealed that some of the $V\gamma 2V\delta 2^+$ T cell clones that expanded during primary BCG infection were also identified in the $V\gamma 2V\delta 2^+$ T cell subpopulation that expanded after reinfection [see supplemental material (19)]. These molecular analyses provide evidence that $V\gamma 2V\delta 2^+$ T cells that underwent polyclonal expansion during a primary BCG infection can mount a memory or recall response after a secondary BCG infection.

Given that $V\gamma 2V\delta 2^+$ T cells contribute to adaptive immune responses, it seems likely that the clonally expanded cells that emerge after BCG infection were involved in the control of active BCG replication in the macaques. To address this possibility, we monitored active BCG infection by quantitating BCG colony counts in the blood (20) and determined the kinetics of $V\gamma 2V\delta 2^+$ T cell expansions during the course of the BCG infection. The expansion of $V\gamma 2V\delta 2^+$ T cells was associated with a clearance of detectable BCG bacteremia (Fig. 3). Our recent studies suggest that the decline of BCG colony-forming units (CFU) in the blood is dependent on the immune competence, because the enhanced T cell suppression during simian immunodeficiency virus–BCG (SIV-BCG) coinfection results in a prolonged BCG bacteremia in the blood (20,21). Thus, the kinetics of BCG CFU counts and $V\gamma 2V\delta 2^+$ T cells in BCG-infected macaques suggest that $V\gamma 2V\delta 2^+$ T cells contribute to the immune containment of

avirulent mycobacterial infections in macaques, and these findings are consistent with the antimicrobial activities of $\gamma\delta$ T cells observed in mice (11–16).

Lastly, we sought to determine whether the adaptive immune responses of $V\gamma 2V\delta 2^+$ T cells seen in the BCG infection could also be identified in *M. tuberculosis* infection (19). After a *M. tuberculosis* aerosol challenge (exposure to aerosolized *M. tuberculosis*), the naïve macaques exhibited a primary expansion of $V\gamma 2V\delta 2^+$ T cells in the bronchoalveolar lavage (BAL) fluid (Fig. 4A). A rapid recall expansion of $V\gamma 2V\delta 2^+$ T cells was also apparent in BAL fluid after a *M. tuberculosis* aerosol challenge of the BCG-vaccinated macaques (Fig. 4A). Similar to what was observed after the pulmonary BCG exposure (unpublished observations), *M. tuberculosis* aerosol challenge did not induce an apparent expansion of $V\gamma 2V\delta 2^+$ T cells in the blood of naïve and BCG-vaccinated macaques in the acute infection. The rapid recall expansion of alveolar $V\gamma 2V\delta 2^+$ T cells in the BCG-vaccinated, *M. tuberculosis*-infected macaques coincided with the development of protective immunity to the acutely fatal form of tuberculosis (Fig. 4B). The BCG-vaccinated macaques remained clinically healthy during a 2.5-month period of follow up after *M. tuberculosis* challenge. In contrast, the unvaccinated macaques developed lethargy, anorexia, and wasting; they subsequently died and they showed evidence of miliary tuberculosis 4 to 6 weeks after *M. tuberculosis* aerosol challenge. We realize that the BCG-vaccinated, *M. tuberculosis*-infected monkeys may progress to a subclinical form of tuberculosis, because they did exhibit detectable *M. tuberculosis* and its mRNA in BAL cells (Fig. 4B). Nevertheless, this potential outcome would not negate our observation that a rapid recall response of $V\gamma 2V\delta 2^+$ T cells coincided with immune protection against the acutely fatal tuberculosis in monkeys.

Our studies provide strong evidence that $V\gamma 2V\delta 2^+$ T cells, like $\alpha\beta^+$ T cells, contribute to adaptive immune responses in mycobacterial infections. The adaptive immune responses of $V\gamma 2V\delta 2^+$ T cells are indeed driven by BCG nonpeptide antigens (19). The contribution of these cells to vaccine protection against tuberculosis was demonstrated in the juvenile rhesus model. BCG-mediated protection against the fatal form of tuberculosis has been reported in children, although its protective efficacy for chronic pulmonary tuberculosis in adults and monkeys is controversial (22–29). It seems that the antigen specificity, TCR diversity, and recall features of $V\gamma 2V\delta 2^+$ T cells separate this $\gamma\delta$ T cell subset from innate cells including peripheral mononuclear cells (PMN), monocytes, and natural killer (NK) cells as well as those $\gamma\delta$ T cells that express invariant $\gamma\delta$ TCR (30,31). The unique ability of $V\gamma 2V\delta 2^+$ T cells to mount rapid and large expansions in mycobacterial infections suggests that vaccine-elicited $V\gamma 2V\delta 2^+$ T cell immunity may be both possible and useful. Thus, $V\gamma 2V\delta 2^+$ T cells may broadly contribute to both innate and acquired immunity against microbial infections.

Acknowledgments

Supported by NIH RO1 grants HL64560 and RR13601 (to Z.W.C.). We thank members at Viral Pathogenesis for technical support and W. R. Jacobs at Albert Einstein College of Medicine for providing *M. tuberculosis* H37Rv used in the study.

References and Notes

1. Pfeffer K, Schoel B, Gulle H, Kaufmann SH, Wagner H. Eur J Immunol 1990;20:1175. [PubMed: 2141570]
2. Tanaka Y, et al. Proc Natl Acad Sci USA 1994;91:8175. [PubMed: 8058775]
3. Burk MR, Mori L, De Libero G. Eur J Immunol 1995;25:2052. [PubMed: 7621879]
4. Poquet Y, et al. Res Immunol 1996;147:542. [PubMed: 9127886]
5. Tanaka Y, Morita CT, Nieves E, Brenner MB, Bloom BR. Nature 1995;375:155. [PubMed: 7753173]
6. Constant P, et al. Science 1994;264:267. [PubMed: 8146660]

7. Bukowski JF, Morita CT, Brenner MB. *Immunity* 1999;11:57. [PubMed: 10435579]
8. Kunzmann V, Bauer E, Wilhelm M. *N Engl J Med* 1999;340:737. [PubMed: 10068336]
9. Morita CT, et al. *Immunity* 1995;3:495. [PubMed: 7584140]
10. Morita CT, Mariuzza RA, Brenner MB. *Springer Semin Immunopathol* 2000;22:191. [PubMed: 11116953]
11. Mombaerts P, Arnoldi J, Russ F, Tonegawa S, Kaufmann SH. *Nature* 1993;365:53. [PubMed: 8361537]
12. Ladel CH, et al. *Eur J Immunol* 1995;25:838. [PubMed: 7705416]
13. Hiromatsu K, et al. *J Exp Med* 1992;175:49. [PubMed: 1530961]
14. D'Souza CD, et al. *J Immunol* 1997;158:1217. [PubMed: 9013962]
15. Sciammas R, Kodukula P, Tang Q, Hendricks RL, Bluestone JA. *J Exp Med* 1997;185:1969. [PubMed: 9166426]
16. Moore TA, Moore BB, Newstead MW, Standiford TJ. *J Immunol* 2000;165:2643. [PubMed: 10946293]
17. Zhou D, et al. *J Immunol* 1999;162:2204. [PubMed: 9973496]
18. Chen ZW, et al. *J Med Primatol* 2000;29:143. [PubMed: 11085576]
19. Supplemental material is available on *Science* Online at www.sciencemag.org/cgi/content/full/295/5563/2255/DC1
20. Shen Y, et al. *Infect Immun* 2002;70:869. [PubMed: 11796622]
21. Shen Y, et al. *J Virol* 2001;75:8690. [PubMed: 11507214]
22. Rodrigues LC, Diwan VK, Wheeler JG. *Int J Epidemiol* 1993;22:1154. [PubMed: 8144299]
23. Colditz GA, et al. *JAMA* 1994;271:698. [PubMed: 8309034]
24. Barclay WR, et al. *Am Rev Respir Dis* 1973;107:351. [PubMed: 4632221]
25. Colditz GA, et al. *Pediatrics* 1995;96:29. [PubMed: 7596718]
26. Janicki BW, Good RC, Minden P, Affronti LF, Hymes WF. *Am Rev Respir Dis* 1973;107:359. [PubMed: 4632222]
27. Ribi E, et al. *J Infect Dis* 1971;123:527. [PubMed: 5000470]
28. McMurray DN. *Clin Infect Dis* 2000;30(suppl 3):S210. [PubMed: 10875785]
29. Langermans JA, et al. *Proc Natl Acad Sci USA* 2001;98:11497. [PubMed: 11562492]
30. Mukasa A, Born WK, O'Brien RL. *J Immunol* 1999;162:4910. [PubMed: 10202036]
31. Itohara S, et al. *Nature* 1990;343:754. [PubMed: 2154700]

Fig. 1.

BCG infection induced a major expansion of Vγ2Vδ2⁺ T cells in the macaques. **(A)** Changes in relative and absolute numbers of CD3⁺ peripheral blood lymphocytes (PBL) that are Vγ⁺, Vδ⁺, or Vγ2Vδ2⁺ T cells after BCG inoculation. **(B)** A major expansion of Vγ2Vδ2⁺ T cells in pulmonary alveoli and intestinal mucosae but not in lymph nodes of the macaques. Mm, rhesus monkeys (*Macaca mulatta*). The monkeys, 3 to 15 years of age, were inoculated intravenously with 10⁶ CFU of BCG.

Fig. 2. BCG reinfection induced a recall expansion of circulating Vγ2Vδ2⁺ T cells. The left panel shows a rapid increase in γδ⁺ T cells in CD3⁺ PBL after a second BCG inoculation, whereas the right panel shows that the responses of circulating Vγ2Vδ2⁺ T cells after BCG reinfection were greater in magnitude and longer in duration than the response of these cells after the first BCG infection. BCG reinfection of the monkeys that recovered from the primary active infection was done by intravenous inoculation of them with 10⁸ CFU of BCG 3 to 5 months after the first BCG inoculation.

Fig. 3. $V\gamma 2V\delta 2^+$ T cell expansion was associated temporally with the decreasing trend of active BCG infection. Shown is the kinetics of peripheral blood BCG CFUs (ml) and $V\gamma 2V\delta 2^+$ T cell expansions after the first (**top**) and second (**bottom**) BCG infection. Data shown are the means of values with the error bars of SEM from four infected animals.

Fig. 4.

Rapid recall expansion of Vγ2Vδ2⁺ T cells after *M. tuberculosis* aerosol challenge was associated with immunity to acutely fatal tuberculosis in BCG-vaccinated monkeys. **(A)** *M. tuberculosis* aerosol challenge induced primary and recall expansions of alveolar Vγ2Vδ2⁺ T cells in four naïve (left) and four BCG-vaccinated (right) macaques, respectively. Both percentage and absolute numbers of alveolar Vγ2Vδ2⁺ T cells are shown after the *M. tuberculosis* aerosol challenge. **(B)** A reduced number of viable BCG (CFU/ml) and Ag85 mRNA in BAL cells of BCG-vaccinated monkeys. The naïve macaques died from acutely fatal tuberculosis on days 25, 28, 38, and 41 after the *M. tuberculosis* aerosol challenge. Necropsy showed miliary tuberculosis in the lung, liver, spleen, and kidney of the dead macaques. The BCG-vaccinated macaques remained clinically healthy during a 2.5-month follow up after *M. tuberculosis* aerosol challenge ($P < 0.001$). The eight monkeys, all of which were 2 years of age, were challenged with 400 to 500 *M. tuberculosis* organisms by aerosol route (21). The BCG vaccination was done by intravenous inoculation of 10⁶ CFU 6 weeks before the *M.*

tuberculosis aerosol challenge. Quantitation of *M. tuberculosis* Ag85B mRNA was done with the use of real-time quantitative polymerase chain reaction (PCR) (21).